|
|
Emotional and Behavioral Disorders in Children and AdolescentsPublished by: BCC Research Published: Sep. 1, 2005 - 186 Pages Table of ContentsINTRODUCTION STUDY OBJECTIVES REASONS FOR DOING THIS STUDY CONTRIBUTIONS OF THE STUDY SCOPE OF THE STUDY METHODOLOGY INFORMATION SOURCES ABOUT THE AUTHOR RELATED BCC REPORTS BCC ONLINE SERVICES DISCLAIMER SUMMARY Summary Table: WORLDWIDE SALES OF DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) Summary Figure: WORLDWIDE SALES OF DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) OVERVIEW DEFINITIONS OF EMOTIONAL AND/OR BEHAVIOR DISORDERS DEFINITIONS OF EMOTIONAL AND/OR…(CONTINUED) TERMINOLOGY CLASSIFICATION OF EMOTIONAL AND BEHAVIORAL DISORDERS Table 1 DSM CLASSIFICATIONS* OF EMOTIONAL AND BEHAVIORAL DISORDERS Table 2 CLASSIFICATION OF EMOTIONAL AND BEHAVIORAL DISORDERS (AS DONE FOR THIS REPORT) CAUSES OF EMOTIONAL AND BEHAVIOR DISORDERS BIOLOGICAL FACTORS PSYCHOPHYSIOLOGICAL AND GENETIC INFLUENCES NEUROLOGICAL DYSREGULATION ENVIRONMENTAL FACTORS SCHOOL-RELATED FACTORS PARENT PSYCHOLOGICAL FACTORS FAMILIAL CONTRIBUTIONS Divorce, Marital Distress and Violence Family Adversity and Insularity Parent-child Interactions Other Family Characteristics CHARACTERISTICS OF STUDENTS WITH BEHAVIOR DISORDERS INTELLIGENCE AND ACHIEVEMENT Social Skills and Interpersonal Relationships Antisocial Behavior Withdrawn Behavior MANIFESTATIONS OF BEHAVIOR DISORDERS TYPES OF DISORDERS ANXIETY DISORDERS TYPES OF ANXIETY DISORDERS CAUSES SYMPTOMS AND TREATMENT Psychological Treatments Psychopharmacological Treatments Environmental Treatments SEVERE DEPRESSION CAUSES SYMPTOMS AND TREATMENT Symptoms and Treatment (Continued) BIPOLAR DISORDER SYMPTOMS AND TREATMENT Symptoms and Treatment (Continued) ATTENTION DEFICIT HYPERACTIVITY DISORDER SYMPTOMS AND TREATMENT AUTISM SYMPTOMS AND TREATMENT SCHIZOPHRENIA SYMPTOMS AND TREATMENT LEARNING DISORDERS SYMPTOMS AND TREATMENT CAUSES CONDUCT DISORDER SYMPTOMS AND TREATMENT EATING DISORDERS SYMPTOMS AND TREATMENTS DRUG CLASSIFICATION CLASSIFICATION BASED ON MECHANISM OF ACTION BENZODIAZEPINES Table 3 BENZODIAZEPINES SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) Table 4 SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) TRICYCLIC ANTIDEPRESSANTS Table 5 TRICYCLIC ANTIDEPRESSANTS ANTIHISTAMINES Table 6 ANTIHISTAMINES MAJOR TRANQUILIZERS OR NEUROLEPTICS Table 7 MAJOR TRANQUILIZERS, NEUROLEPTICS OR ANTIPSYCHOTICS MOOD STABILIZERS Table 8 MOOD STABILIZERS CNS STIMULANTS Table 9 CNS STMULANTS NONSTIMULANTS Table 10 NONSTMULANTS ATYPICAL ANTIPSYCHOTICS Table 11 ATYPICAL ANTIPSYCHOTICS CLASSIFICATION BASED ON THERAPEUTIC CATEGORY ANTIANXIETY DRUGS Table 12 DRUGS USED FOR ANTIANXIETY DISORDERS Table 12 (CONTINUED) Clorazepate Chlordiazepoxide Chlorpromazine Clonezepam Diazepam Doxipine Fluoxetine Hydrochloride Fluphenazine Fluvoxamine Maleate Haloperidol Hydroxyzine Nortriptyline Oxazepam Sertraline Hydrochloride Thioridazine Thioxanthene Trifluperazine SEVERE DEPRESSION DRUGS Table 13 DRUGS USED FOR SEVERE DEPRESSION Amitryptyline Fluoxetine Hydrochloride Impramine Sertraline Hydrochloride BIPOLAR DISORDER DRUGS Table 14 DRUGS USED FOR BIPOLAR DISORDER Lithium Divalproex Carbamazepine ATTENTION DEFICIT HYPERACTIVITY DISORDER (ADHD) DRUGS Table 15 DRUGS USED FOR ATTENTION DEFICIT HYPERACTIVITY DISORDER Amphetamines Dextroamphetamine Methylphenidate Pemoline Atomoxetine Hydrochloride AUTISTIC DISORDER DRUGS Table 16 DRUGS USED FOR AUTISTIC DISORDER TREATMENT Risperidone SCHIZOPHRENIA DRUGS Table 17 DRUGS USED FOR SCHIZOPHRENIA SAFETY, EFFICACY AND REGULATION SAFETY AND EFFICACY SAFETY AND EFFICACY (CONTINUED) Table 18 LABELLED USE AND APPROVED AGE FOR AGENTS TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS REGULATORY ASPECTS REGULATORY ASPECTS (CONTINUED) REGULATORY ASPECTS (CONTINUED) Table 19 DRUGS RECEIVING A BOXED WARNING, OTHER PRODUCT LABELING CHANGES, AND A MEDICATION GUIDE PERTAINING TO PEDIATRIC SUICIDAL TENDENCIES DRUG APPROVALS Table 20 DEVICES AND IMPLANTS APPROVED BY THE FDA 2000-APRIL 2005 INDUSTRY STRUCTURE BEHAVIOR AND EMOTIONAL DISORDER DRUG INDUSTRY MARKET BY COMPANY ANTIANXIETY Table 21 MARKET SHARES OF MANUFACTURERS OF ANTIANXIETY AGENTS TO TREAT BEHAVIOR AND EMOTIONAL DISORDERS, 2004 (%) Figure 1 MARKET SHARES OF MANUFACTURERS OF ANTIANXIETY AGENTS TO TREAT BEHAVIOR AND EMOTIONAL DISORDERS, 2004 (%) Antidepressants Table 22 MARKET SHARES OF MANUFACTURERS OF ANTIDEPRESSANT AGENTS TO TREAT BEHAVIOR AND EMOTIONAL DISORDERS, 2004 (%) Figure 2 MARKET SHARES OF MANUFACTURERS OF ANTIDEPRESSANT AGENTS TO TREAT BEHAVIOR AND EMOTIONAL DISORDERS, 2004 (%) Bipolar Disorders Table 23 MARKET SHARES OF MANUFACTURERS PRODUCING DRUGS FOR BIPOLAR DISORDER TREATMENT, 2004 (%) Figure 3 MARKET SHARES OF MANUFACTURERS PRODUCING BIPOLAR DISORDER DRUGS, 2004 (%) ADHD Disorders Table 24 MARKET SHARES OF MANUFACTURERS PRODUCING ADHD DRUGS FOR TREATING BEHAVIOR AND EMOTIONAL DISORDERS, 2004 (%) Figure 4 MARKET SHARES OF MANUFACTURERS OF ADHD DRUGS FOR TREATING BEHAVIOR AND EMOTIONAL DISORDERS, 2004 (%) Autistic Disorders Table 25 MARKET SHARES OF MANUFACTURERS OF AUTISTIC DISORDER DRUGS, 2004 (%) Figure 5 MARKET SHARES OF MANUFACTURERS OF AUTISTIC DISORDER DRUGS, 2004 (%) Schizophrenia Table 26 MARKET SHARES OF MANUFACTURERS OF DRUGS FOR TREATING SCHIZOPHRENIA, 2004 (%) Figure 6 MARKET SHARES OF MANUFACTURERS OF DRUGS FOR TREATING SCHIZOPHRENIA, 2004 (%) Learning Disorders Table 27 MARKET SHARES OF MANUFACTURERS OF DRUGS FOR TREATING LEARNING DISORDERS, 2004 (%) Figure 7 MARKET SHARES OF MANUFACTURERS OF DRUGS FOR TREATING LEARNING DISORDERS, 2004 (%) Eating Disorders Table 28 MARKET SHARES OF MANUFACTURERS OF DRUGS FOR TREATING EATING DISORDERS, 2004 (%) Figure 8 MARKET SHARES OF MANUFACTURERS OF DRUGS TO TREAT EATING DISORDERS, 2004 (%) Conduct Disorders Table 29 MARKET SHARES OF MANUFACTURERS OF CONDUCT DISORDER DRUGS, 2004 (%) Figure 9 MARKET SHARES OF MANUFACTURERS OF CONDUCT DISORDER DRUGS, 2004 (%) MARKET BY DRUG TYPES TOTAL MARKET SIZE Table 30 WORLDWIDE SALES OF DRUGS BY TYPE TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) Table 31 PROPORTION OF TYPES OF DRUGS BEING USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2004 Figure 10 PROPORTION OF TYPES OF DRUGS BEING USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2004 (%) SALES BY TYPE OF THERAPEUTIC CATEGORY BENZODIAZEPINES Table 32 WORLDWIDE SALES OF BENZODIAZEPINES USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) Figure 11 WORLDWIDE SALES OF BENZODIAZEPINES USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIS) Table 33 WORLDWIDE SALES OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) Figure 12 WORLDWIDE SALES OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) TRICYCLIC ANTIDEPRESSANTS Table 34 WORLDWIDE SALES OF TRICYCLIC ANTIDEPRESSANTS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) Figure 13 WORLDWIDE SALES OF TRICYCLIC ANTIDEPRESSANTS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) ANTIHISTAMINES Table 35 WORLDWIDE SALES OF ANTIHISTAMINES USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) Figure 14 WORLDWIDE SALES OF ANTIHISTAMINES USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) MAJOR TRANQUILIZERS, NEUROLEPTICS OR ANTIPSYCHOTICS Table 36 WORLDWIDE SALES OF MAJOR TRANQILIZERS, NEUROLEPTICS OR ANTIPSYCHOTICS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) Figure 15 WORLDWIDE SALES OF MAJOR TRANQILIZERS, NEUROLEPTICS OR ANTIPSYCHOTICS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) MOOD STABILIZERS Table 37 WORLDWIDE SALES OF MOOD STABILIZERS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) Figure 16 WORLDWIDE SALES OF MOOD STABILIZERS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) CNS STIMULANTS Table 38 WORLDWIDE SALES OF CNS STIMULANTS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) Figure 17 WORLDWIDE SALES OF CNS STIMULANTS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) NONSTIMULANTS Table 39 WORLDWIDE SALES OF NONSTIMULANTS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) Figure 18 WORLDWIDE SALES OF NONSTIMULANTS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) ATYPICAL ANTIPSYCHOTICS Table 40 WORLDWIDE SALES OF ATYPICAL ANTIPSYCHOTICS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) Figure 19 WORLDWIDE SALES OF ATYPICAL ANTIPSYCHOTICS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) MARKET BY DISORDERS TOTAL MARKET SIZE Table 41 WORLDWIDE SALES OF DRUGS BY TYPE OF DISORDER TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) Table 42 PERCENTAGE SHARE OF GLOBAL MARKET FOR DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS BY DISORDER TYPE, 2004 (%) Figure 20 SHARES OF GLOBAL MARKET FOR DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS BY DISORDER TYPE, 2004 (%) SALES BY TYPE OF DRUGS ANTIANXIETY AGENTS Table 43 WORLDWIDE SALES OF ANTIANXIETY DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) Figure 21 WORLDWIDE SALES OF ANTIANXIETY DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) DRUGS USED TO TREAT DEPRESSION Table 44 WORLDWIDE SALES OF ANTIDEPRESSANTS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) Figure 22 WORLDWIDE SALES OF ANTIDEPRESSANTS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) DRUGS USED TO TREAT BIPOLAR DISORDER Table 45 WORLDWIDE SALES OF DRUGS TO TREAT BIPOLAR EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) Figure 23 WORLDWIDE SALES OF DRUGS TO TREAT BIPOLAR EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) ADHD DRUGS Table 46 WORLDWIDE SALES OF ADHD DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) Figure 24 WORLDWIDE SALES OF ADHD DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) AUTISTIC DISORDER DRUGS Table 47 WORLDWIDE SALES OF AUTISTIC DISORDER DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) Figure 25 WORLDWIDE SALES OF AUTISTIC DISORDER DRUGS USED TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) SCHIZOPHRENIA DRUGS Table 48 WORLDWIDE SALES OF SCHIZOPHRENIA DRUGS TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) Figure 26 WORLDWIDE SALES OF SCHIZOPHRENIA DRUGS TO TREAT EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) DRUGS FOR LEARNING DISORDERS Table 49 WORLDWIDE SALES OF DRUGS USED TO TREAT LEARNING DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) Figure 27 WORLDWIDE SALES OF DRUGS USED TO TREAT LEARNING DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) DRUGS FOR EATING DISORDERS Table 50 WORLDWIDE SALES OF DRUGS USED TO TREAT EATING DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) Figure 28 WORLDWIDE SALES OF DRUGS USED TO TREAT EATING DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) CONDUCT DISORDER DRUGS Table 51 WORLDWIDE SALES OF DRUGS TO TREAT CONDUCT DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) Figure 29 WORLDWIDE SALES OF DRUGS TO TREAT CONDUCT DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) DEMOGRAPHICS OVERVIEW ANTIANXIETY AGENTS Table 52 DEMOGRAPHICS OF ANTIANXIETY DRUG USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%) Figure 30 DEMOGRAPHICS OF ANTIANXIETY DRUG USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%) ANTIDEPRESSANTS Table 53 DEMOGRAPHICS FOR ANTIDEPRESSANT DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%) Figure 31 DEMOGRAPHICS FOR ANTIDEPRESSANT DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%) BIPOLAR DISORDER DRUGS Table 54 DEMOGRAPHICS FOR BIPOLAR DISORDER DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%) Figure 32 DEMOGRAPHICS FOR BIPOLAR DISORDER DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%) ADHD DRUGS Table 55 DEMOGRAPHICS FOR ADHD DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%) Figure 33 DEMOGRAPHICS FOR ADHD DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%) AUTISTIC DISORDER DRUGS Table 56 DEMOGRAPHICS FOR AUTISTIC DISORDER DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%) Figure 34 DEMOGRAPHICS FOR AUTISTIC DISORDER DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%) SCHIZOPHRENIA DRUGS Table 57 DEMOGRAPHICS FOR DRUGS USED TO TREAT SCHIZOPHRENIA IN CHILDREN AND ADOLESCENTS, 2004 (%) Figure 35 DEMOGRAPHICS FOR DRUGS USED TO TREAT SCHIZOPHRENIA IN CHILDREN AND ADOLESCENTS, 2004 (%) LEARNING DISORDER DRUGS Table 58 DEMOGRAPHICS FOR LEARNING DISORDER DRUGS IN CHILDREN AND ADOLESCENTS, 2004 (%) Figure 36 DEMOGRAPHICS FOR LEARNING DISORDER DRUGS IN CHILDREN AND ADOLESCENTS, 2004 (%) EATING DISORDER DRUGS Table 59 DEMOGRAPHICS FOR EATING DISORDER DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%) Figure 37 DEMOGRAPHICS FOR EATING DISORDER DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%) CONDUCT DISORDER DRUGS Table 60 DEMOGRAPHICS FOR CONDUCT DISORDER DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%) Figure 38 DEMOGRAPHICS FOR CONDUCT DISORDER DRUGS USAGE IN CHILDREN AND ADOLESCENTS, 2004 (%) NEW DEVELOPMENTS NEW DEVELOPMENTS AstraZeneca Table 61 NEW DRUGS FROM ASTRAZENECA Bristol-Myers Squibb Table 62 NEW DRUGS FROM BRISTOL-MYERS SQUIBB Celgene Table 63 NEW DRUGS FROM CELGENE GlaxoSmithKline Table 64 NEW DRUGS FROM GLAXOSMITHKLINE Table 64 (CONTINUED) Johnson & Johnson Table 65 NEW DRUGS FROM JOHNSON & JOHNSON Merck Table 66 NEW DRUGS FROM MERCK Novartis Table 67 NEW DRUGS FROM NOVARTIS Pfizer Table 68 NEW DRUGS FROM PFIZER Roche Table 69 NEW DRUGS FROM ROCHE Sanolfi-Aventis Table 70 NEW DRUGS FROM SANOFI-AVENTIS Shire Table 71 NEW DRUGS FROM SHIRE Solvay Table 72 NEW DRUGS FROM SOLVAY Wyeth Table 73 NEW DRUGS FROM WYETH PATENTS PATENTS BY YEAR Table 74 ANNUAL NUMBER OF PATENTS RELATING TO TREATMENTS FOR EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2001-2005 Figure 39 TOTAL PATENTS FOR EMOTIONAL AND BEHAVIORAL DISORDER TREATMENTS IN CHILDREN AND ADOLESCENTS, 2001-2005 Figure 40 ANNUAL SHARE OF PATENTS FOR EMOTIONAL AND BEHAVIORAL DISORDER TREATMENTS IN CHILDREN AND ADOLESCENTS, 2001-2005 (%) PATENTS BY CATEGORY Table 75 TOTAL NUMBER OF PATENTS RELATING TO TREATMENTS FOR EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS BY CATEGORY, 2001-2005 Figure 41 TOTAL NUMBER OF PATENTS RELATING TO TREATMENTS FOR EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS BY CATEGORY, 2001-2005 Figure 42 SHARE OF TOTAL NUMBER OF PATENTS RELATING TO TREATMENTS FOR EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS BY CATEGORY, 2001-2005 (%) SIGNIFICANT PATENTS OF 2005 Table 76 SIGNIFICANT PATENTS FOR DRUGS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS, 2005 PATENTS BY COMPANY Table 77 U.S. PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS BY COMPANY, 2001-2005 Table 77 (CONTINUED) PATENTS BY COUNTRY Table 78 U.S. PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS BY COUNTRY, 2001-2005 (NUMBER OF PATENTS) Table 78 (CONTINUED) Figure 43 U.S. PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS BY COUNTRY, 2001-2005 (NUMBER OF PATENTS) Table 79 TRENDS OF PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS ISSUED BY COUNTRY, 2005-2001 Figure 44 TRENDS OF PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS ISSUED BY COUNTRY, 2001-2005 Figure 45 SHARE OF PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS ISSUED BY COUNTRY, 2001-2005 (%) PATENTS BY ASSIGNEE Table 80 NUMBER AND SHARE OF U.S. PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS BY ASSIGNEE, 2001-2005 Figure 46 NUMBER OF U.S. PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS BY ASSIGNEE, 2001-2005 (NUMBER OF PATENTS) Figure 47 SHARES OF U.S. PATENTS RELATING TO BEHAVIORAL AND EMOTIONAL DISORDER DRUGS BY ASSIGNEE, 2001-2005 (%) INTERNATIONAL ASPECTS TOTAL MARKET SIZE Table 81 REGIONAL SALES OF TREATMENTS FOR BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) REGIONAL SALES BY TYPE OF DISORDER ANTIANXIETY AGENTS Table 82 REGIONAL SALES OF ANTIANXIETY AGENTS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) Figure 48 REGIONAL SALES OF ANTIANXIETY AGENTS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) ANTIDEPRESSANTS Table 83 REGIONAL SALES OF ANTIDEPRESSANTS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) Figure 49 REGIONAL SALES OF ANTIDEPRESSANTS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) BIPOLAR DISORDER DRUGS Table 84 REGIONAL SALES OF BIPOLAR DISORDER DRUGS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) Figure 50 REGIONAL SALES OF BIPOLAR DISORDER DRUGS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) ADHD DRUGS Table 85 REGIONAL SALES OF ADHD DRUGS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) Figure 51 REGIONAL SALES OF ADHD DRUGS USED TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) AUTISTIC DISORDER DRUGS Table 86 REGIONAL SALES OF AUTISTIC DISORDER DRUGS TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) Figure 52 REGIONAL SALES OF ADHD DRUGS TO TREAT BEHAVIORAL AND EMOTIONAL DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) SCHIZOPHRENIA DRUGS Table 87 REGIONAL SALES OF DRUGS TO TREAT SCHIZOPHRENIC DISORDERS IN CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) Figure 53 REGIONAL SALES OF DRUGS TO TREAT SCHIZOPHRENIC DISORDERS IN CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) Learning Disorder Drugs Table 88 REGIONAL SALES OF LEARNING DISORDER DRUGS TO TREAT CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) Figure 54 REGIONAL SALES OF LEARNING DISORDER DRUGS TO TREAT CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) Conduct Disorder Drugs Table 89 REGIONAL SALES OF CONDUCT DISORDER DRUGS USED TO TREAT CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) Figure 55 REGIONAL SALES OF CONDUCT DISORDER DRUGS USED TO TREAT CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) Eating Disorder Drugs Table 90 REGIONAL SALES OF EATING DISORDER DRUGS TO TREAT CHILDREN AND ADOLESCENTS, THROUGH 2010 ($ MILLIONS) Figure 56 REGIONAL SALES OF EATING DISORDER DRUGS TO TREAT CHILDREN AND ADOLESCENTS, 2003-2010 ($ MILLIONS) PREVELANCE OF EMOTIONAL AND BEHAVIORAL DISORDERS IN CHILDREN AND ADOLESCENTS IN SELECTED COUNTRIES UNITED STATES UNITED KINGDOM INDIA CHINA China (Continued) COMPANY PROFILES ABBOTT LABORATORIES ALLIANT PHARMACEUTICALS BRISTOL-MYERS SQUIBB CELEGENE CELLTECH PHARMACEUTICALS ELI LILLY GLAXOSMITHKLINE PLC JOHNSON & JOHNSON JOHNSON & JOHNSON (CONTINUED) MALLINCKRODT MEDICAL NOVARTIS PHARMACEUTICAL CORP. OVATION PHARMACEUTICALS PFIZER, INC. ROCHE SHIRE SOLVAY VALEANT PHARMACEUTICALS AbstractThe report contains:
Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||